Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old at the time of signing the consent form
• People who have been confirmed through laboratory testing (biopsy or cell samples) to have non-small cell lung cancer (NSCLC)
• People who fit into one of three groups: (1) advanced or metastatic NSCLC without certain genetic changes (EGFR wild-type and ALK-negative), with no more than one prior round of chemotherapy for advanced disease; (2) advanced or metastatic NSCLC without those same genetic changes and no prior treatment at all; or (3) advanced or metastatic NSCLC with a specific genetic change (EGFR activating mutation) but no ALK gene change, where previous targeted therapy (EGFR-TKI) has stopped working
• People who are able to provide a fresh or previously collected tumour tissue sample for testing
• People who have at least one measurable tumour that can be tracked on scans, and whose cancer is not only in the skin or bones
• People who are relatively well and active in daily life (rated 0 or 1 on a standard health scale used in cancer trials), with an expected survival of at least 12 weeks
• People whose blood tests show their organs and bone marrow are functioning well enough (confirm with trial site for specific thresholds)
• People of childbearing potential (both female and male) who agree to use effective contraception during the treatment period and for 6 months after the last dose
• People who voluntarily agree to take part, sign the consent form, and attend all required visits and procedures

Who may not be able to join:

• People whose lung cancer contains small cell lung cancer (SCLC) components
• People with a history of other cancers
• People who have cancer that has spread to the brainstem, the lining of the brain or spinal cord, or who have spinal cord compression
• People with currently active cancer spread to the brain or central nervous system
• People whose tumour, on CT or MRI scans, is wrapped around or very close to major blood vessels in a way that raises concern about serious bleeding risk
• People with serious or uncontrolled heart disease or significant heart-related symptoms requiring treatment (confirm with trial site for specific heart conditions listed)
• People with a non-infectious lung condition called interstitial lung disease (ILD), a history of lung inflammation that required steroid treatment, or serious loss of lung function due to existing lung disease
• People with uncontrolled ongoing health conditions such as uncontrolled high blood pressure, uncontrolled diabetes, or significant fluid build-up around the lungs, heart, or in the abdomen
• People with active hepatitis B or hepatitis C infection, known HIV infection or AIDS, or a positive syphilis antibody test
• People with known active tuberculosis
• People with a known allergy or serious reaction to the study drug or its ingredients, or a history of severe allergic reactions to similar medications (monoclonal antibodies)
• People who have previously received an organ transplant or a stem cell transplant from a donor
• People who are pregnant or currently breastfeeding
• People whose condition worsens significantly during the screening period before receiving the first dose, such as a rapid decline in general health or pain that requires changes to pain medication
• People who, in the trial doctor's judgement, have any other condition that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.